AACE ePoster Library

EXPERIENCE USING V-GO® IN PATIENTS WITH LATENT AUTOIMMUNE DIABETES OF THE ADULT (LADA) AND TYPE 1 DIABETES
AACE ePoster Library. Lajara R. 05/13/15; 97794; 272
Dr. Rosemarie Lajara
Dr. Rosemarie Lajara
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Objective:
To date, no data has been published regarding the specific use of V-Go in patients diagnosed with LADA or with type 1 diabetes (T1DM).

The objective of this study was to assess the efficacy and safety of patients with these forms of diabetes sub-optimally controlled on Multiple Daily Injections (MDI) switched to V-Go.

Methods:
A sub analysis of patients with LADA or T1DM was conducted from a larger study conducted at Diabetes America, Texas evaluating patients poorly controlled on previous therapies switched to V-Go.

Data was collected using an electronic medical records database.

Changes from baseline were examined for HbA1c, fasting plasma glucose (FPG), weight, patient reported insulin dosing, and reported hypoglycemia.

Exclusion criteria included patients ≥21 years of age and previously using insulin with an HbA1c >7.0%.

Results or Case Presentation:
Twenty one patients with LADA or T1DM with elevated blood glucose were switched to V-Go therapy from an insulin regimen of MDI. Mean baseline characteristics were: age 44 yrs, weight 88 kg (193 lbs), duration of diabetes 19 yrs, HbA1c 9.6%, FPG 245 mg/dl, basal insulin dose 38 U/day, and total daily insulin dose (TDD) 66 U/day.

Mean exposure to V-Go therapy at the 1st follow-up visit (FV) was 103 days at the time of abstract submission. An additional 2nd FV in 14 patients and a 3rd FV in 11 patients (mean duration 200 and 297 days respectively) were available at the time of these analyses.

Significant reductions in HbA1c from baseline were observed at the 1st FV (-1.2, p=0.0004) with a decrease in TDD (12 U/day, p=0.0494). Reductions in HbA1c were maintained in patients with a 2nd and 3rd FV.

A decrease in TDD of 18% (12 U/day, p <0.05) from baseline and a reduction in units required per kilogram were observed at the 1st FV. Insulin reductions were maintained in those patients with additional follow-up visits available.

A mean change in FPG of -81 mg/dl (p<0.05) was observed despite a 21% decrease (-8 U/day, p<0.05) in basal insulin dose at 1st FV.

Change in weight at 1st FV (+0.85 kg, p=0.329) was not significant.

Fewer patients reported problematic hypoglycemia on V-Go therapy compared to previous multiple daily injection therapy (7 patients compared to 10 patients).

Discussion:
Many patients with diabetes are unsuccessful at reaching and maintaining therapeutic goals.

Multiple daily injections can be a burden for those with LADA or T1DM and data is limited in this patient type using V-Go therapy.

Our data suggests that V-Go offers an efficacious approach to deliver basal-bolus therapy and reduce the burden of glucose management through simplified delivery.

Larger controlled studies are needed to fully evaluate the use of V-Go in this patient population.

Conclusion:
Switching to V-Go resulted in significant HbA1c reductions, decreased insulin requirements and no increase in reported hypoglycemia for patients with uncontrolled LADA or T1DM.
Objective:
To date, no data has been published regarding the specific use of V-Go in patients diagnosed with LADA or with type 1 diabetes (T1DM).

The objective of this study was to assess the efficacy and safety of patients with these forms of diabetes sub-optimally controlled on Multiple Daily Injections (MDI) switched to V-Go.

Methods:
A sub analysis of patients with LADA or T1DM was conducted from a larger study conducted at Diabetes America, Texas evaluating patients poorly controlled on previous therapies switched to V-Go.

Data was collected using an electronic medical records database.

Changes from baseline were examined for HbA1c, fasting plasma glucose (FPG), weight, patient reported insulin dosing, and reported hypoglycemia.

Exclusion criteria included patients ≥21 years of age and previously using insulin with an HbA1c >7.0%.

Results or Case Presentation:
Twenty one patients with LADA or T1DM with elevated blood glucose were switched to V-Go therapy from an insulin regimen of MDI. Mean baseline characteristics were: age 44 yrs, weight 88 kg (193 lbs), duration of diabetes 19 yrs, HbA1c 9.6%, FPG 245 mg/dl, basal insulin dose 38 U/day, and total daily insulin dose (TDD) 66 U/day.

Mean exposure to V-Go therapy at the 1st follow-up visit (FV) was 103 days at the time of abstract submission. An additional 2nd FV in 14 patients and a 3rd FV in 11 patients (mean duration 200 and 297 days respectively) were available at the time of these analyses.

Significant reductions in HbA1c from baseline were observed at the 1st FV (-1.2, p=0.0004) with a decrease in TDD (12 U/day, p=0.0494). Reductions in HbA1c were maintained in patients with a 2nd and 3rd FV.

A decrease in TDD of 18% (12 U/day, p <0.05) from baseline and a reduction in units required per kilogram were observed at the 1st FV. Insulin reductions were maintained in those patients with additional follow-up visits available.

A mean change in FPG of -81 mg/dl (p<0.05) was observed despite a 21% decrease (-8 U/day, p<0.05) in basal insulin dose at 1st FV.

Change in weight at 1st FV (+0.85 kg, p=0.329) was not significant.

Fewer patients reported problematic hypoglycemia on V-Go therapy compared to previous multiple daily injection therapy (7 patients compared to 10 patients).

Discussion:
Many patients with diabetes are unsuccessful at reaching and maintaining therapeutic goals.

Multiple daily injections can be a burden for those with LADA or T1DM and data is limited in this patient type using V-Go therapy.

Our data suggests that V-Go offers an efficacious approach to deliver basal-bolus therapy and reduce the burden of glucose management through simplified delivery.

Larger controlled studies are needed to fully evaluate the use of V-Go in this patient population.

Conclusion:
Switching to V-Go resulted in significant HbA1c reductions, decreased insulin requirements and no increase in reported hypoglycemia for patients with uncontrolled LADA or T1DM.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies